Back to VitaDAO blog

VitaDAO Closes $4.1m Fundraising Round With Pfizer And Shine Capital

January 30, 2023

2023 kicks off with strong support for longevity research and a huge step for decentralized science(DeSci) 

We are excited to announce that we have closed a $4.1m fundraising round from strategic members including Pfizer Ventures, Shine Capital, L1 Digital; decentralised science and web3 organisations Beaker DAO and Spaceship DAO; and longevity enthusiasts including Balaji Srinivasan (former CTO of Coinbase and General Partner at a16z) and Joe Betts-LaCroix (Retro Biosciences) and many others.

The proceeds from the fundraise will be used to fund further longevity research projects and precede the spinout of VitaDAO's first biotech startups, scheduled in the first quarter of 2023, as well as further investment in commercialization and licensing of its IP-NFT assets through its partnership with Molecule DAO.

“2022 was a highly successful year for VitaDAO, and the quality of research we have seen has been impressive,” says Laurence Ion, Steward of the Dealflow Working Group. “We’ve also seen some of our projects move rapidly to the next stage in development -- such as entering into clinical trials with Mantis Photonics and new data from the Morten Scheibye-Knudsen Lab at the University of Copenhagen and the Victor Korolchuk Lab at the University of Newcastle. This has further proven that a highly aligned community can contribute to advancing the science and clinical innovation in longevity research.”

The fundraising is an important milestone for VitaDAO and will allow the organisation to accelerate its mission of extending human life and healthspan. With these new funds, VitaDAO will be able to fund cutting-edge longevity research, commercialise new technologies that target human aging, and build out its global community of experts and enthusiasts.

Pfizer is the first pharma to vote on DAO proposal (within VitaDAO), and also participates in VitaDAO in many other ways, including dealflow, scientific evaluation, incubation, and commercialization.

In 2022, we grew our community to include over 9000 enthusiasts, researchers, and contributors, as well as deployed over $3.5m in more than 15 projects researching the diseases of ageing, and the repair of damage associated with the hallmarks of ageing. 

All researchers are welcome to apply for funding, including professors, post-docs, research scientists, and even students. 

VitaDAO wishes to thank its contributors for their support.  

How to get involved

VitaDAO is defined as an active and diverse community of contributors.  Everyone can contribute to VitaDAO. We’re looking for researchers to identify and assess longevity projects and non-researchers to help with tech, legal, awareness, and operations If you’d like to get involved, a great first step is to join our Discord.

Do you want to stay up to date with VitaDAO? Subscribe to our newsletter, add the vitadao calendar, and visit our twitter

For any media requests, reach out to and check out our press kit.

Recommended Reading